The Hematologist

banner image

New Podcast: Trainees

Drs. Nelson, May, and Cruz help trainees navigate the upcoming 61st ASH Annual Meeting, discussing sessions, events, and features that could benefit the trainee community.

Play here
banner image

Surrogate Endpoints for Cure in DLBCL: Are We There Yet?

Dr. Jacobson observes relapses in patients with diffuse large b-cell lymphoma treated with immunochemotherapy.

Read more
banner image

Ask the Hematologists

Drs. Chancellor Donald and Cindy Leissinger discuss their approach to acquired thrombotic thrombocytopenic purpura (TTP) with multiple relapses.

Read more
Current Issue Static Feature

Current Issue

September/October 2019
Volume 16, Issue 5

Read current issue

President's Column

Presidents Column - Kenneth AndersonProfessor and Chair of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
Global Thoughts Become Global Actions
August 27, 2019

Dr. Silverstein discusses ASH global initiatives and the many ways the Society supports international hematologists.

View all president's column articles

  • CAR T-cell Therapy: An Update on Coverage and Reimbursement
    August 14, 2019

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • 2018 ASH Advocacy Activities
    December 11, 2018

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
    December 11, 2018

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care
    December 11, 2018

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

View all Policy News